> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Panel to Review Clarus Therapeutics Testosterone Replacement
- URL: https://www.fdaweb.com/panel-to-review-clarus-therapeutics-testosterone-replacement/
- Published: 2017-11-22T12:00:00.000Z
- Updated: 2026-09-14T23:03:12.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5140189

*Federal Register* notice: FDA has announced a 1/9/2018 Bone, Reproductive and Urologic Drugs Advisory Committee meeting in Hyattsville, MD. Panel members will discuss a Clarus Therapeutics NDA for testosterone undecanoate capsules, indicated for testosterone replacement in males for conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired) and hypogonadotropic hypogonadism (congenital or acquired). To view the notice, click [here](https://www.gpo.gov/fdsys/pkg/FR-2017-11-22/pdf/2017-25295.pdf?ref=fdaweb.com).